Drug General Information (ID: DDIGOK50IB)
Drug Name			Amphotericin B (lipid complex)		Drug Info		Ganciclovir		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antifungal Agents				Antiviral Agents
Structure

Mechanism of Amphotericin B (lipid complex)-Ganciclovir Interaction (Severity Level: Moderate)
Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Amphotericin B (lipid complex)				Ganciclovir
Mechanism		Nephrotoxicity				Nephrotoxicity
Key Mechanism Factor 1
		Factor Name		Nephrotoxicity
		Factor Description		The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood.
Mechanism Description		Increased risk of nephrotoxicity by the combination of Amphotericin B (lipid complex) and Ganciclovir

Recommended Action
Management		Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Valcyte (valganciclovir) Roche Laboratories, Nutley, NJ.